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Abstract
Computational models using metabolic reconstructions for in silico simulation of metabolic disorders such as type 2
diabetes mellitus (T2DM) can provide a better understanding of disease pathophysiology and avoid high experimentation
costs. There is a limited amount of computational work, using metabolic reconstructions, performed in this field for the
better understanding of T2DM. In this study, a new algorithm for generating tissue-specific metabolic models is presented,
along with the resulting multi-confidence level (MCL) multi-tissue model. The effect of T2DM on liver, muscle, and fat in MKR
mice was first studied by microarray analysis and subsequently the changes in gene expression of frank T2DM MKR mice
versus healthy mice were applied to the multi-tissue model to test the effect. Using the first multi-tissue genome-scale
model of all metabolic pathways in T2DM, we found out that branched-chain amino acids’ degradation and fatty acids
oxidation pathway is downregulated in T2DM MKR mice. Microarray data showed low expression of genes in MKR mice
versus healthy mice in the degradation of branched-chain amino acids and fatty-acid oxidation pathways. In addition, the
flux balance analysis using the MCL multi-tissue model showed that the degradation pathways of branched-chain amino
acid and fatty acid oxidation were significantly downregulated in MKR mice versus healthy mice. Validation of the model
was performed using data derived from the literature regarding T2DM. Microarray data was used in conjunction with the
model to predict fluxes of various other metabolic pathways in the T2DM mouse model and alterations in a number of
pathways were detected. The Type 2 Diabetes MCL multi-tissue model may explain the high level of branched-chain amino
acids and free fatty acids in plasma of Type 2 Diabetic subjects from a metabolic fluxes perspective.
Citation: Kumar A, Harrelson T, Lewis NE, Gallagher EJ, LeRoith D, et al. (2014) Multi-Tissue Computational Modeling Analyzes Pathophysiology of Type 2
Diabetes in MKR Mice. PLoS ONE 9(7): e102319. doi:10.1371/journal.pone.0102319
Editor: Thierry Alquier, CRCHUM-Montreal Diabetes Research Center, Canada
Received August 19, 2013; Accepted June 18, 2014; Published July 16, 2014
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: Funding for the study was provided by the Intramural program of the National Institute of Diabetes and Digestive and Kidney Diseases, National
Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: beten@jhu.edu
Introduction
Type 2 Diabetes Mellitus (T2DM), the most common form of
Diabetes in America, is becoming a global pandemic with the
greatest increase in cases in many developing countries. The
pathophysiology of T2DM primarily involves defects in three
organ systems– liver, peripheral target tissues (skeletal muscle and
fat), and pancreatic b-cells [1]. Insulin resistance in the peripheral
target tissues, primarily skeletal muscle, is considered the primary
reason for insulin resistance in T2DM [2].
In the patients with T2DM, withdrawal of insulin treatment has
been shown to be associated with increased levels of branched-
chain amino acids (BCAAs) in the plasma [3]. Moreover,
metabolite profiling from the plasma of T2DM patients [4]
revealed BCAAs as the key-biomarkers during the progression of
T2DM. It is shown that the concentrations of BCAAs in plasma,
liver, and skeletal muscle are higher in T2DM conditions such as
in the Zucker diabetic rat [5]. Another study performed on
hyperglycemic/T2DM Finnish males revealed high plasma level
of BCAAs [6] too. Additionally, it has been shown that high levels
of BCAAs in plasma of T2DM subjects are associated with
conditions of insulin-resistance [7–12].
It is also known that elevated free fatty acid (FFA) levels in
plasma is linked to T2DM in patients [13]. One of the studies [14]
on the effect of high plasma FFA levels, pointed out the
contribution of high FFA levels in plasma on the impaired insulin
response of the T2DM subjects.
In contrast to the wealth of knowledge available for the
concentrations of circulating BCAAs and FFAs in T2DM patients,
the actual mechanisms leading to these changes at the metabolic
and genetic levels are less understood. With the emergence of
systems biology tools associated with high-throughput data, it is
now feasible to create in silico genome scale metabolic
reconstruction models to study the causes of various metabolic
disorders [15]. After completion of a global human metabolic
network [16], Recon1, constraint-based modeling became feasible
to study metabolic disorders in silico. Accounting for more than
3000 human metabolic reactions, Recon1 provides a firm basis for
studying human metabolism and metabolic disorders such as
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e102319
cancer, diabetes, obesity, and inherited gene and enzyme
deficiencies [15].
Following Recon1 coming into existence, several tissue-specific
models have also been generated [17–22]. Recon1 in itself is not
sufficient for modeling specific tissues as different tissues exhibit
different physiological and hence metabolic behaviors. Increased
efforts are creating multi-tissue metabolic models to study the
pathophysiology of human metabolic disorders [23].
Insulin resistance leading to Type 2 Diabetes Mellitus (T2DM)
is regulated by more than one tissue system requiring analysis at
multi-tissue level. Major tissues involved in T2DM are skeletal
muscle, liver, adipose, pancreas, brain, and gastrointestinal tract
[24]. As far as the level of metabolites is concerned, skeletal
muscle, liver, and adipose tissues are the major role players in
secreting these metabolites into the blood by various biochemical
pathways. Metabolite concentration levels (such as amino acids
levels) from T2DM subjects’ blood is readily available in literature,
allowing comparison of an in silico model to T2DM phenotype.
The current study introduces a comprehensive multi-tissue-specific
model to study interdependence of hepatocytes, mycoytes, and
adipocytes in the T2DM condition. Table 1 shows a summary of
some different models including the model for the current study
(Kumar et al.) [17,18,20,25,26]. Each model provides specific
advantages and limitation for specific applications. Models can
vary in size and scope and also tissue distribution. For example,
while some models are specific for certain tissues, the current
Kumar model expands the scope to include three tissues.
Moreover, microarray data used in our study contextualizes the
reconstruction according to the three different tissues (liver, WAT,
and skeletal muscle). Furthermore, we used microarray data for
three different tissues from the same animals. While we recognize
that the current approach incorporates this data from a different
organism (mice) into a model based on human metabolism, the
similarity in physiological responses across species makes such an
approach reasonable in the absence of fully validated models and
data sets for each species. Most of the studies involving T2DM and
insulin resistance utilize data from insulin-resistant or diabetic
animal models, such as Zucker fatty (ZF) and Zucker diabetic fatty
rats (ZDF)[27], high-fat-fed mice[28], muscle IGF-1 receptor–
lysine–arginine (MKR) mice[29,30], and lep/lep mice[31]. A
common feature of these animal models is that all models have
manifested insulin resistance and often exhibit islet dysfunction as
occurs in the early stages of type 2 diabetes in humans. It is, in our
opinion, valid to use MKR mice and Zucker diabetic fatty rat data
for making predictions on humans’ T2DM phenotypes. To
validate the model, its capability to predict expected phenotypes
from known genotypes was tested. For this purpose, a publically
available comprehensive database for genes and genetic pheno-
types, the Online Mendelian Inheritance in Man (OMIM)
database was used. This was followed by a comparison between
constraint-based simulation results and the levels of plasma amino
acid in the Zucker diabetic rat after gene expression data for the
three tissues from the diabetic MKR mouse compared to normal
control mice [32].
Results
A.1 Multi-confidence level (MCL) multi-tissue model
Before generating the model, an algorithm was applied to
generate a list of high confidence, medium confidence, and low
confidence reactions, based on the source of a particular reaction.
The high confidence list comprised reactions from published
literature and was not altered by the algorithm; the medium
confidence list comprised of reactions from online databases such
as HPRD, etc.; and the low confidence list comprised of all
remaining reactions that weren’t present in high and medium
confidence reaction lists, as shown in Figure 1 (detailed in
Materials and Methods). The final high confidence reaction list
(Ch) consists of 1110 reactions and 1593 metabolites. The final
medium confidence reaction list (Cm) consists of 1099 reactions
and 1643 metabolites. The final low confidence reaction list (Cx)
consists of 4433 reactions and 3679 metabolites. The algorithm
required six iterations before completing to give multi-confidence
level (MCL) multi-tissue model with 4704 reactions and 3131
metabolites. Completion is indicated by the fact that the objective
function for the whole model is at a maximum for a particular set
of flux distributions and no more reactions can be added in
subsequent iterations (detailed in Materials and Methods).
A.2 Validation using Online Mendelian Inheritance in Man
(OMIM) Database
N From the OMIM database [33], 17 disorders were chosen and
characterized with regard to increases or decreases in
metabolite level in the blood as shown in Figure 2 [22]. Each
of the disorders involves changes in the amino acid levels. The
phenotype of each of these disorders is outlined in Figure 2
above. Each disorder has a set of associated genes, as listed in
Figure 2, which can be used to map to reactions in silico. S-
Adenosylhomocysteine hydrolase is associated with AHCY
gene deficiency [34]. Alkaptonuria is associated with HGD
gene deficiency [35]. Argininemia is associated with mutation
in ARG1 gene [36]. Cystinuria is associated with mutations in
SLC3A1 and SLC7A9 genes [37]. Lysinuric protein intoler-
ance is associated with mutation in SLC7A7 gene [38].
Formiminotransferace deficiency is associated with mutation in
FTCD gene [39]. Histidinemia is associated with mutation in
HAL gene [40]. Homocystinuria is associated with mutation in
CBS gene [41]. Hyperprolinemia is associated with mutation
in PRODH gene [42]. Maple syrup urine disease is associated
with mutation in DBT, BCKDHB, and BCKDHA genes [43].
Methionine adenosyltransferase deficiency is caused by
mutation in MAT1A gene [44]. Methylmalonic aciduria is
caused by mutation in MUT gene [45]. Phenylketonuria is
caused by mutation in PAH gene [46]. Hyperphenylalanin-
emia is associated with mutation in QDPR [47]. Tyrosinemia,
Type I is caused by mutation in FAH gene [48]. Tyrosinemia,
type III is caused by mutation in HPD gene [49]. Glycine
encephalopathy is associated with mutation in AMT, GLDC,
and GCSH genes [50]. In this validation, the reactions
associated with these genes were removed and simulation of
the in silico model was run to predict the phenotype of the
disease associated with removing that particular gene(s). The
predicted phenotype was then compared to the actual
phenotype from the OMIM database. Exchange reactions tell
about the concentration and the exchange flux balances
indicate the increase or decrease in concentration of a
metabolite in the model in the blood/extracellular compart-
ment. This analysis was performed on the MCL multi-tissue
model, Recon1, and the multi-tissue version of Recon1
(modeling the three tissues: adipose, liver, and skeletal muscle).
The results from simulations of Recon1 and the multi-tissue
version of Recon1 served as benchmarks to compare to the
simulations of MCL multi-tissue model, as shown in receiver-
operator curves (ROC) in Figure 3. ROC curves portray the
trade-off between true positive rate (TPR) and false positive
rate (FPR) predictor of a model as the decision threshold of a
parameter is varied.
Multi-Tissue Computational Modeling in MKR Mice
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Recon1 and the multi-tissue version of Recon1 have an
identical curve which is understandable as a multi-tissue version
of Recon1 is just a combination of Recon1 models of the three
tissues and the external exchange compartment; however, it is
necessary to test the differences between the two because the
number of type III cycles can increase in the multi-tissue version of
Recon1. A type III cycle is one of three types of extreme pathways
that can exist in a reaction network (type I, type II, and type III)
and could cause the behavior of the multi-tissue version to be
different than the single tissue version of Recon1. Figure 3
illustrates that the MCL multi-tissue model reaches higher true
positive rates as compared to Recon1. Also, all data points other
than the last one at (1,1) are clustered in an area with a very low
false positive rate. This indicates that all models evaluated in this
experiment performed as expected. The area under the curve
(AUC) provides a quantitative measure of the performance of each
model. The AUC of the MCL multi-tissue model is 0.7151, and
the AUC of Multi – Recon1 and Recon1 is 0.6719, and AUC of a
random selector (not shown) is approximately 0.3866.
A.3 Validation using Type 2 Diabetes Gene Expression
Change
Subsequent validation analysis involved the application of
microarray data from MKR T2DM mice to the aforementioned
in silico models. The microarray data of the two sets was
compared and genes that had statistically significant (with p-value
,0.05) fold changes were tabulated. These differentially expressed
genes were then mapped to Recon1 and the MCL multi-tissue
model to determine sets of upregulated and downregulated
reactions. The bounds of these reactions were changed according
to the procedure defined elsewhere (Materials and Methods). The
resulting differences in the exchange reactions flux bounds in both
models were compared with amino acid data for the Zucker
diabetic fatty rat from the literature [5], as shown in Table 2. With
Table 1. A comparison of different models.
Kumar Bordbar Jerby Gille Mardinoglu Recon1
Intracellular Reaction 2202 518 1056 1081 6160 2180
Genes 1496 931 - - 1809 1496
Unique Metabolites 610 413 729 777 2497 1509
Compartments 4 4 6 6 8 7
A comparison of intracellular reaction, number of distinct genes, number of unique metabolites, and total compartments in different metabolic reconstructions.
doi:10.1371/journal.pone.0102319.t001
Figure 1. Multi-tissue model building workflow. Recon1, downloaded from BiGG database, is the basis of building this multi-tissue model for
liver, skeletal muscle, and adipose tissues. From the Recon1 individual compartment models, the algorithm first loads a randomized flux distribution
matrix representing randomization of linear programming (LP) problems. Then a Boolean vector describing activity (1 = active, 0 = inactive) of each
reaction is created. Then scoring for each column of the flux distribution is done. If the objective score is greater than 0, corresponding reaction is
added in the construction. This process is repeated until highest objective score is greater than 0, implying objective function is at its maximum. This
generates a partial model. Then the whole process is repeated again based on the partial model, until there is no change in model size between one
iteration to another iteration.
doi:10.1371/journal.pone.0102319.g001
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respect to the reference model with no change; any positive value
corresponds to upregulated and any negative value corresponds to
downregulated.
The difference between the two pairs (Recon 1 and MCL multi-
tissue model) of columns in Table 2 represent two different
analyses in which reactions were used in calculating increases and
decreases in plasma concentration of the corresponding amino
acids. The columns labeled ‘‘Ex-Recon1’’ and ‘‘Ex-MCL Multi-
tissue Model’’ represent analyses in which the exchange reactions
were used solely to determine the increases and decreases in
concentration of amino acids in the blood/plasma. The columns
labeled ‘‘Trans-Recon1’’ and ‘‘Trans-MCL Multi-tissue Model’’
represent analyses in which transport reactions were used to
determine the increases and decreases in different pathways’
fluxes. In this instance, a transport reaction is defined as a reaction
that moves a particular amino acid from the cytosol to the
extracellular/blood compartment. An exchange reaction is a
special type of reaction that only exists in these types of
computational models and represent flow of metabolites across a
system boundary [51].
The first two rows in Table 3 represent the analyses using
exchange reactions, and as expected the MCL multi-tissue model
outperforms Recon1 in every category (a lower FPR is better). The
last two rows in Table 3 represent the analyses using the transport
reactions. Table 3 shows that the MCL multi-tissue model
significantly outperformed Recon1 when using exchange reac-
tions, but the results appear to be much closer when using
transport reactions. The MCL multi-tissue model outperformed
Recon1 in every category except recall (recall is same as true
positive rate). ROC curves for the differences in flux bounds of the
exchange reactions and transport reactions are shown in Figure 4
and Figure 5 respectively.
These ROC curves clearly demonstrate the differences between
Recon1 and MCL multi-tissue model by providing the clear
differences in the area under the curve (AUC) between the two
models. In Figure 4, the MCL multi-tissue model outperformed
Recon1, which isn’t surprising given the results in Table 3. In the
figures 4 and 5, there are more points in Recon1 because of the
fact that there are greater number of reactions in Recon1 as
compared to the multi-tissue model and therefore downregulated
genes were mapped to more reactions. The AUC of the fold
change simulations of MCL multi-tissue model using Transport
reactions in Figure 4 is 0.3100; the AUC of Recon1 in Figure 4 is
0.0412 and the AUC of random selector (not shown) is 0.3866.
The AUC’s of the MCL multi-tissue model using Exchange
reactions and Recon1 in Figure 5 are 0.5048 and 0.3998,
respectively, which means that both Recon1 and the MCL
multi-tissue model are better than a random selector for transport
reactions. Thus, the MCL multi-tissue model is consistently above
Recon1 for both transport and exchange reactions and exceeds the
random selector curve for transport reactions but not for exchange
reactions. The random selector curve is based on a set of reactions
generated by random permutation from the entire set of reactions.
Recon1 was highly inaccurate for transport reactions at each
threshold, which demonstrates the difficulty with predicting
increases or decreases of exchange from gene expression fold
changes. The fact that the MCL multi-tissue model displays an
AUC that is roughly 7.5 times greater than the AUC produced by
Recon1 provides further validation for the MCL multi-tissue
model in these analyses, at least compared to other systems
available.
Figure 2. OMIM data used for model validation. Blue and red squares depict an increase and decrease in concentration, respectively. White
squares represent unchanged concentration levels.
doi:10.1371/journal.pone.0102319.g002
Multi-Tissue Computational Modeling in MKR Mice
PLOS ONE | www.plosone.org 4 July 2014 | Volume 9 | Issue 7 | e102319
A.4 MCL multi-tissue model’s application on MKR mice
microarray data
After the two extensive validations outlined in sections 2.1 and
2.2, the model was used to study physiological behaviors during
T2DM condition – higher plasma concentration of branched-
chain amino acids (BCAAs) and free fatty acids (FFAs) in T2DM
subjects. Branched-chain amino acid metabolism has been studied
in T2DM condition previously [10], [52], [53], but none of the
groups have determined metabolic fluxes through relevant
pathways, as described in this study using a robust computational
model. Past studies [18], [17] have focused on a single tissue (such
as liver) for investigating metabolic disorders. However, this
doesn’t give a complete picture of the metabolic disorder. In
another study [20] the investigators studied T2DM on fat, liver,
and muscle tissues using an in silico model which was less
comprehensive in terms of the number of metabolic reactions used
in the one presented in this study. In order to use the MCL multi-
tissue model for predicting physiological changes in fully T2DM
MKR mice as compared to healthy mice, gene expression data
was first generated for liver, skeletal muscle, and fat tissues for
healthy and diabetic mice. Statistical tests on gene expression data
suggested that several genes were differentially regulated between
MKR and healthy mice. The statistical test – Fisher’s exact test,
providing significance of the association of the experimental gene
expression values and the Ingenuity Pathway Analysis canonical
pathways, was done using the Ingenuity software (www.ingenuity.
com). From gene expression fold change analysis in the three
tissues, it was found that for BCAA degradation and FA oxidation
pathways, some of the genes are upregulated and some are
downregulated in liver, while the same were predominantly
downregulated in the T2DM MKR mice’s fat and muscle tissues
when compared to their healthy euglycemic littermates, as shown
in Table 4.
The liver tissues’ FA degradation pathway genes did not provide
a clear explanation of high concentration of FFAs in the plasma of
T2DM subjects. However, the biosynthesis pathway from
Ingenuity Pathway Analysis (Figure 6) for fatty acids in the liver
tissues of MKR mice does provide an explanation of the
differences in FFA levels in healthy and diseased subjects’ plasma.
There is a clear increase in the gene expression patterns for
biosynthesis of fatty acids in liver and a decrease in fatty acid
oxidation in skeletal muscle and fat tissues, thereby accumulating
more free fatty acids in the plasma of T2DM subjects.
In order to perform systems level analysis of the gene expression
data, to achieve a better understanding of BCAA and FA
metabolism, we next used the gene expression data along with
Figure 3. ROC plot for validation using OMIM data. ROC plot comparing different models using gene-deletion study. This figure demonstrates
the true positive and false positive rates at various threshold values.
doi:10.1371/journal.pone.0102319.g003
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the MCL multi-tissue model to generate flux predictions. Gene
expression data was used for generating a context-specific MCL
multi-tissue network using an algorithm which uses gene
expression data to remove the reactions associated with no gene
expression, thereby creating a context-specific metabolic network
for the in silico T2DM condition simulation. Then, flux variability
analysis is performed to find out the reactions without fluxes,
which are then removed. The remaining reactions then represent
an active context-specific metabolic network. This active model
was used to find out the differences between biochemical reaction
activity between T2DM and healthy states.
Figure 7 (A)–(F) represent the data corresponding to each
subsystem in the three tissues compared to a hypothetical dataset
represented by a random selector. T-scores were obtained for each
subsystem to determine the statistical significance of the degree of
differential expression. The purpose of organizing the data in this
way is to identify particular subsystems affected more greatly by
T2DM. This organization scheme helps filter out small subsystems
that contain all downregulated reactions but have very few
reactions, and therefore do not control the overall behavior of the
model.
Cholesterol metabolism is upregulated in adipose tissue (Figure 7
– D) and downregulated in liver tissue (Figure 7 – B) and muscle
tissue (Figure 7 – C). This can lead to higher cholesterol level in
plasma of T2DM subjects as also observed through actual
measurements [54]. The carnitine shuttle is downregulated in
adipose tissues (Figure 7 – A) and muscle tissues (Figure 7 – C), and
is upregulated in liver tissues (Figure 7 – E). As reported in
literature [14], a downregulated carnitine shuttle leads to insulin
resistance by triglyceride accumulations in the cytosol of the cells
by hampering beta-oxidation. Another interesting observation is
the upregulated N-Glycan degradation in adipose tissues (Figure 7
– C) and downregulated N-Glycan biosynthesis in liver tissues
(Figure 7 – B). The behavior of these pathways leads to altered N-
Glycans structure in the plasma of T2DM subjects [55,56].
Sphingolipid metabolism is upregulated both in adipose tissues
(Figure 7 – D) and muscle tissues (Figure 7 – F), which matches
expectations, as ceramide levels in skeletal muscle of T2DM
Zucker fatty rat were found normal [57,58]. However, there is no
known relation between T2DM and skeletal muscle ceramide level
[59].
It is important to note that in most of the research work done on
studying behavior of these subsystems deal with studying
differences in gene expression in the two physiological conditions;
however, in this study we present differences in fluxes in the
biochemical reactions in the two physiological conditions (T2DM
vs healthy). Figures S1–S15 in File S1 show percentage of
reactions retained by subsystems in the three tissues, fold change
analysis in the three tissues, OMIM data analysis including the
random selector along with zoomed in version, and robustness
analysis results. File S2 provides direction of flux changes
(upregulated or downregulated) in different subsystems along with
the t-scores in adipose, skeletal muscle, and liver tissues in three
individual worksheets corresponding to each tissue type. In the
former method of study, if genes associated with few reactions in a
subsystem are downregulated, then most of the subsystem will be
downregulated because of the steady-state condition. However, in
subsystems with a combination of upregulated and downregulated
genes, the whole subsystem behaves unpredictably, so the flux
results can help decipher such ambiguous situations clearly.
Table 2. Simplified depiction of the validation results.
Amino acid Zucker diabetic fatty rat Ex-Recon1 Ex-MCL multi-tissue Model Trans-Recon1 Trans-MCL multi-tissue Model
Arginine Q q - - Q
Leucine q - - q -
Phenylalanine - q - - -
Cysteine - - - Q -
Glutamine Q - q q -
Serine Q q - q -
Asparagine Q - - q -
Tryptophan Q - - - Q
Proline - Q - - -
Threonine Q - - q -
Aspartate - q q - -
Glycine Q - - Q -
Glutamate q - - Q -
Isoleucine q - q - q
Lysine Q - - - q
Valine q - - q q
Methionine Q q q - q
Tyrosine Q - Q Q Q
Alanine - Q q - -
Histidine Q q Q Q q
The upward arrow (q) depicts higher amino acid level in Zucker diabetic fatty rat versus healthy rat. The downward arrow (Q) depicts lower amino acid level in Zucker
diabetic fatty rat versus healthy rat. (-) depicts no difference in the amino acid level between the two types of rats.
doi:10.1371/journal.pone.0102319.t002
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Discussion
In the present study, microarray technology was used to
elucidate the relation of free fatty acid and branched-chain amino
acids levels under T2DM and normal condition and the gene
expression profiles in three different tissues – liver, muscle, and
adipose of diabetic MKR mice. The findings from microarray
analysis show that MKR mice have a downregulated fatty acid
oxidation profile in muscle and adipose tissues. In liver, the entire
fatty acid oxidation profile is not downregulated. On the contrary,
fatty acid biosynthesis in liver tissues is considerably upregulated as
shown in figure 6. Therefore, a possible explanation for the higher
circulating free fatty acid levels in the diabetic MKR mice is the
upregulated biosynthesis of fatty acids in liver and considerable
lower oxidation of the fatty acids in the muscle and adipose tissues
of the animals. Gene expression for branched-chain amino acids
metabolism is significantly downregulated too. However, mere
downregulation of gene expression does not imply downregulation
of the flux through these pathways. Moreover, using gene
expression data alone doesn’t clearly predict how fast or slow a
biochemical reaction proceeds. However, incorporating metabolic
flux results, based on such computational models, greatly enhances
the understanding of reaction fluxes.
Wang et al. [60] pointed out that comparisons using only
enrichment statistics with gene expression data provides far fewer
predictions as given by model based approaches. There are a
larger number of pathways that can be identified using the model
based approach as compared to using gene expression data alone.
Subsequently, an algorithm for building a multi-tissue model is
presented in the current paper. The algorithm presented in this
paper uses as few linear programming solutions as possible to
achieve an optimal solution, so that the solution can be found in a
reasonable amount of time. The model provides users with the
ability to predict changes in metabolite levels in the medium after
deleting specific metabolic genes, as well as the ability to predict
changes in metabolite concentrations in the plasma/medium after
applying fold changes to specific genes. Other capabilities include
using a quadratic programming solver to apply experimentally
derived fluxes to specific reactions in the model and determining
the remaining fluxes to examine the behavior of the overall model
in given by the experiment [17].
The positive aspect of this approach is that metabolic fluxes can
be predicted; this is important because metabolic fluxes are
difficult to measure in mammalian tissues, and metabolic fluxes
provide essential information used for characterizing phenotypes
Figure 4. ROC plot for exchange flux changes using Zucker fatty rat data. ROC plot of the results generated by comparing the exchange
flux changes determined by applying diabetic and wild-type gene expression data to the MCL multi-tissue model and Recon1 to available literature
data on amino acid concentration changes in the blood/plasma.
doi:10.1371/journal.pone.0102319.g004
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of cellular systems. Flux information can help predict metabolic
biomarkers in blood/plasma [22], and can potentially help predict
causes for certain metabolic disorders. However, due to their
qualitative nature, results from these steady state models should be
thought of as supplements to experiments; they are best used to
help provide potential targets for biological experiments.
Figures S7–S12 in file S1 delineate the results of the fold change
analyses by separating the upregulated and downregulated
reactions by subsystems (pathways). As mentioned before, it is
easier to find out approximately which subsystems are upregulated
or downregulated by microarray analysis, but that does not fully
explain the physical effects of the fold changes in these genes, in
terms of changes in the metabolic fluxes. The results show a
significant downregulation of branched-chain amino acid metab-
olism and fatty acid oxidation in muscle and adipose tissues (there
is some down regulation of branched-chain amino acid metabo-
lism in the liver tissue, but it is less apparent than in the other two
tissues). There are more downregulated reactions than upregulated
reactions. Changes in gene expression can only be assumed to
affect relative enzyme levels, which can only affect upper and
lower flux bounds; therefore, we can assume that more downreg-
ulated reactions are affected than upregulated reactions because a
decrease in the flux bounds represents more restriction than an
increase in flux bounds. This is because reactions with increased
flux bounds can still be forced to have lower fluxes by adjacent
downregulated reactions, whereas reaction with decreased flux
bounds cannot be forced to have higher fluxes by adjacent
upregulated reactions.
Statistical significance of the differential regulation of the
subsystems was calculated by using a two sample t-test (assuming
the second sample is a randomly generated set of upregulated,
downregulated, and unchanged reaction predictions and is of the
same size as the subsystem) to determine the statistical significance
of the subsystem’s deviation from random behavior. For example,
if the subsystem is 100% downregulated with two reactions, then,
intuitively, this is not very statistically relevant because a random
selector can make this selection 1/9 of the time (assuming the
random selector chooses downregulated, upregulated, and un-
changed each 1/3 of the time). Thus, sorting by the t-score of each
subsystem provides a better understanding of the extent of
differential regulation of the subsystems. Figures S1–S12 in file
S1 demonstrate the approximate effect of the gene expression
during T2DM on certain subsystems. As expected branched chain
amino acid metabolism and fatty acid oxidation have very high t-
scores in muscle and adipose tissue. The results regarding the
branched-chain amino acid metabolism is consistent with the
results available in literature [61]. The downregulation of BCAA
metabolism in adipose tissue causes an increase in BCAAs in the
circulation, which is shown by the amino acid transport fluxes.
This increase in circulating BCAAs causes a decrease in BCAA
metabolism in muscle tissue as well [53], which is consistent with
results in this study. Newgard et al. have reported increased
concentration of BCAA in the plasma of T2DM subjects [10].
Although we didn’t have access to in vivo methods of metabolic
flux measurement, we did find evidences supporting our results.
For example, it is reported that gluconeogenesis flux in humans is
decreased in Type 2 Diabetes [62], which is also demonstrated in
our model. In skeletal muscle, free fatty oxidation flux is reduced
implying abnormal mitochondrial function [63–66] which is also
suggested by our results with reduced fatty acid oxidation in
skeletal muscle as well as reduced carnitine shuttle which is
responsible for fatty acid transport across mitochondria. In order
to compare our findings and the above reported findings, we have
reported predictions on the BCAA exchange metabolites. Apart
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from BCAA, other exchange fluxes predictions also resulted from
the analysis, but those predictions’ in vivo validity with respect to
T2DM is not yet confirmed.
The most negative t-score in adipose and muscle tissues is for
the carnitine shuttle subsystem. The ‘Nucleotides’ subsystem is also
strongly downregulated in both muscle and adipose tissue.
Interestingly, liver tissue displays more upregulation than the
other tissues, with the carnitine shuttle subsystem showing
upregulation. Thus, the carnitine shuttle subsystem appears to
be the subsystem most affected in T2DM. The carnitine shuttle is
responsible for transport of long chain fatty acids into mitochon-
dria for oxidation. So, a downregulated carnitine shuttle in adipose
and muscle tissues implies lower metabolism of the FFAs in those
two tissues. Even though the FFA metabolism is higher in liver
because of upregulated carnitine shuttle, the biosynthesis pathway
of fatty acids is also elevated (Figure 6). This explains the overall
high FFA plasma level in T2DM condition. Other subsystems that
appear to be affected strongly include most metabolic subsystems
of bile acid metabolism, cholesterol metabolism, and branched-
chain amino acid metabolism. These subsystems should be studied
in more depth in future studies.
In summary, the integration of microarray data and in silico
predictions via constraint-based modeling has facilitated better
understanding of the reason behind high BCAA and FFA levels in
plasma of T2DM subjects. Prior systems biology studies have
shown the ability of constraint-based models to predict metabolic
biomarkers [22]. Similarly, this model provides the complete set of
biomarker predictions generated by the genetic fold change study.
These metabolites represent potential biomarkers that can
facilitate T2DM studies.
Type 2 diabetes is characterized by two major defects: beta-cell
dysfunction and insulin resistance in peripheral tissues. The exact
alterations in molecular pathways associated with beta-cell
dysfunction in insulin-resistant and diabetic states are not clearly
understood. Most of the studies involving T2DM and insulin
resistance utilize data from insulin-resistant or diabetic animal
models, such as Zucker fatty (ZF) and Zucker diabetic fatty rats
(ZDF) [27], high-fat-fed mice [28], muscle IGF-1 receptor–lysine–
arginine (MKR) mice [29,30], and lep/lep mice [31]. A common
feature of all these animal models is that all models have
manifested insulin resistance and often exhibit islet dysfunction
as occurs in the early stages of type 2 diabetes in humans.
Figure 5. ROC plot for transport reaction flux changes using Zucker fatty rat data. ROC plot of the results generated by the flux changes in
transport reactions determined by applying T2DM and wild-type gene expression data to the MCL multi-tissue model and Recon1and then
comparing the results to available literature data on amino acid concentration changes in the plasma of T2DM Zucker diabetic fatty rat.
doi:10.1371/journal.pone.0102319.g005
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Therefore, it is, in our opinion, valid to use MKR mice and
Zucker diabetic fatty rat data for making predictions on humans’
T2DM phenotypes.
In a mammalian system, the specific objective of a particular
function of a cell, at a given time and under certain conditions, is
difficult to identify, whereas in unicellular systems, the objective
function can be assumed to be the maximization of cell growth.
This is because mammalian systems are much more complex,
especially when attempting to define models for different tissues,
because each tissue has a different objective. One may consider
that there is an over-arching objective function when considering a
system that defines the overall human body as a linear
combination of partial Recon1’s associated with each tissue, but
this again is difficult to define, because the objective of maximizing
biomass in unicellular organisms only applies during the expo-
nential growth phase. Thus, maximizing biomass in mammalian
systems may be applicable, but only during the growth phase of
the mammal.
Materials and Methods
B.1 Animal Studies
All animal study protocols were approved by the Mount Sinai
School of Medicine Institutional Animal Care and Use Committee
(IACUC). Mice were housed in The Mount Sinai School of
Medicine Center for Comparative Medicine and Surgery, an
Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC) and Office of Laboratory Animal
Welfare (OLAW) accredited facility, where animal care and
maintenance were provided.
Male 10-weeks old FVB/N – MKR mice were used for the
microarray studies. Generation and characterization of MKR
mice have been described elsewhere [32]. Mice were kept on a 12-
h light/dark cycle, they were allowed free access to diet (Picolab
rodent diet #5053) and fresh water. Death of the mice was caused
by subjecting them to CO2. Liver, Skeletal muscle, and fat tissues
were flash frozen in liquid nitrogen, stored at 280uC, and shipped
on dry ice to NIDDK/NIH facility for further processing.
B.2 RNA Sampling
Total RNA from the liver, fat, and skeletal muscle tissues was
isolated for three biological replicates for both diseased and
healthy animal subjects. Qiagen’s Microarray Tissue Mini Kit
(Qiagen GmbH, Germany) was used for RNA isolation purpose
according to the manufacturer’s instructions. Purified total RNA
was quantified using a spectrophotometer (Thermo Scientific Ltd).
The absorbance values at 260 and 280 nm were used for assessing
the quality of the sample. Only the samples with greater than 1.80
260/280 absorbance ratio were used for microarray analysis [67].
B.3 Microarrays procedure, Statistical analysis and
Biological Inference
RNA quality was tested using bioanalyzer (RNA Nano assay in
the Expert 2100 software, Agilent Technologies, CA) and RIN
(RNA Integrity Number) values were above 8.0 for all the samples.
100 ng of RNA from each sample was amplified to generate
cDNA using NUGEN Applause WT – Amp ST system (NuGEN
Technologies, CA), according to the manufacturer’s instructions.
2.5 mg of cDNA was fragmented and biotinylated using Encore
Biotin module (NUGEN Technologies, CA). Resultant sample mix
with hybridization reagents (Affymetrix Inc. CA) and injected into
Affymetrix Mouse Gene 1.0 ST arrays and incubated for
18+2 hours in hybridization oven rotating at 60 rpm at 45uC
(Affymetrix Inc., CA). Arrays were processed using Affymetrix 450
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Fluidic stations using wash and stain kit (Affymetrix Inc.). Chips
were scanned using Affymetrix GeneChip scanner 3000 operated
by Gene Chip Operating Software, version 1. 4 (GCOS 1.4) and
generated.CEL.CHP and RPT files. To access the efficiency of
cDNA synthesis Poly A controls (dap, lys, phe, thr- Affymetrix
Inc.) was spiked to the samples and hybridization controls (bioB,
bioD, bioC and Cre, Affymetrix Inc.) were added to monitor
labeling efficiency according to the manufacturer’s instructions.
The microarray raw data was analyzed using software Partek
genomics suite, version 6.3 Copyright 2008 Partek Inc., St. Louis,
MO, USA. Raw data were subjected to Robust Multichip Average
(RMA) quantile normalization to remove biases introduced by
technical and experimental effects. All expression data were log
base 2 -transformed to get near normal distribution for accurate
statistical inference. Quality control by visualizing the data using
Principal Component Analysis cluster plot ensured that no outliers
were included for the analysis. Next, two-way ANOVA analysis
was performed to obtain a set of differentially expressed genes. A
filter of P-value ,0.05 and Fold-change .1.5 times was applied to
get the significantly differentially expressed genes list. The results
of the microarray analysis have been deposited to National Center
for Biotechnology Information (NCBI) repository and can be
accessed with Gene Omnibus Expression accession: GSE51866.
The significantly differentially expressed genes list was exported
to – Ingenuity Pathway Analysis (Ingenuity Systems, www.
ingenuity.com) for finding biological inference. Ingenuity Pathway
Analysis is an online software used to study relationship between
genes, proteins, and biological reactions. More technical details
about the Ingenuity Pathway Analysis’ capabilities can be accessed
from the Ingenuity Systems website. Statistically significant genes
from Partek analysis were overlaid on the Ingenuity Pathway
Analysis global molecular network, which is based on information
from other databases such as KEGG, HumanCyc, etc. in the
Ingenuity knowledge base after applying a filter on species type
(mouse) and tissue type (e.g. adipose).
Figure 6. Canonical biosynthesis pathway of fatty acids in liver using microarray data. Mapping of gene expression for liver tissues on
biosynthesis of fatty acids, using Ingenuity Pathway Analysis software. Red color shows upregulated gene expression in MKR mice versus Healthy
mice.
doi:10.1371/journal.pone.0102319.g006
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B.4 Tissue-specific Model Building Algorithm
Published, detailed reconstruction of human metabolism
(Recon1) was downloaded from the BiGG database in SBML
format [68,69]. The models were created, maintained, and altered
using the COBRA toolbox in MATLAB version 2010a [70]. A
three tissue version of Recon1 was generated by adding prefixes -
‘A:’, ‘H:’, and ‘M:’ to each reaction name and suffixes - [Adp],
[Hep], and [Msc] to each metabolite for adipocytes, hepatocytes,
and skeletal muscle tissue respectively. The extracellular compart-
ment is shared between all three tissues and only one set of
reactions comprising of only extracellular metabolites was
maintained in the MCL multi-tissue model. After removing all
reactions associated with dead-end metabolites from the model,
the size of the three tissue version of Recon1 becomes 6644
reactions with 4103 metabolites.
The algorithm for trimming down the general three tissue
version of Recon1 is built by minimizing the number of linear
programming problems needed to trim the reconstruction [17,22].
The algorithm contains three sets of reactions: a high-confidence
set, a medium-confidence set, and a low-confidence set. The high
confidence set of reactions was created based on literature results
containing confirmed protein expression in the three tissues and
were mapped to specific reactions in Recon1 for specific tissue
types [71–101]. The medium confidence set of reactions was
obtained from tissue-specific data from publically available
databases HPRD [102–104], UniProt [105], and Brenda [106]
and their online databases with tissue-specific data [107–109]. The
low confidence set of reactions was the list of remaining reactions
that were not in either the high or medium confidence sets.
The overall goal of this algorithm is: (1) maintain all high
confidence reactions and (2) maximize the number of medium
confidence reactions minus 0.5 multiplied by the number of low
confidence reactions in the final trimmed version of the
reconstruction. Statement (2) can be considered the objective
function of the algorithm as shown below –
Maximize CM\RP{0:5  CX\RP
The value 0.5 reflects equal probability of obtaining the most
parsimonious model as well as including a maximal number of
moderate probability reactions in the partial model using above
algorithm [17].
Rp is a partial subset of reactions from Recon1 that defines the
solution space for the tissue-specific reconstruction, CM and CX
are the medium and low confidence set of reactions, respectively.
The algorithm makes more efficient use of all of the information
gained from a single linear programming (LP) solution. Every
reconstruction can be broken down into elementary flux modes;
these can be thought of as the simplest possible flux distributions.
Therefore, every reconstruction is a linear combination of
elementary flux modes, and thus, each linear programming
solution is a smaller linear combination of elementary flux modes.
Ideally, the algorithm would identify all elementary flux modes in
a reconstruction or even LP solution and find the optimal
combination from the elementary flux modes, but as of now, this is
computationally infeasible due to combinatorial explosion [110].
Elementary flux modes have been determined for smaller
networks, but cannot be found for more complex networks like
Figure 7. MCL multi-tissue model predictions on different pathways. (A), (B), and (C) represent downregulated pathways (subsystem) for
adipose, liver, and skeletal muscle tissues respectively. (D), (E), and (F) represent upregulated pathways for adipose, liver, and skeletal muscle tissues
respectively. They are organized by t-score; the more negative the t-score, the more down-regulated the subsystem and the more positive the t-
score, the more up-regulated the subsystem.
doi:10.1371/journal.pone.0102319.g007
Multi-Tissue Computational Modeling in MKR Mice
PLOS ONE | www.plosone.org 12 July 2014 | Volume 9 | Issue 7 | e102319
Recon1. However, LP solutions represent feasible flux distribu-
tions that are typically much smaller than the size of the final
networks. Final networks can also be thought of as linear
combinations of all of these possible linear programming solutions.
Therefore, the algorithm pre-loads a very large matrix with
information on around 10,000–20,000 randomly generated flux
distributions represented by linear programming solutions. The
randomization of the solutions is the randomization of the
objective functions of the associated linear programming prob-
lems. The algorithm randomly selects a few high confidence and
medium confidence reactions to be maximized in the objective
function; low confidence reactions will never be in the objective
function. Then, a Boolean vector is created which describes the
activity of each reaction in the network (1 for active and 0 for
inactive). This vector represents one flux distribution and also
represents one column in the large matrix of random flux
distributions (the large matrix is named fdMatrix). The rows of
each Boolean column vector, and consequently the matrix,
represent distinct reactions in the general network. The creation
of this matrix represents the second step of the algorithm.
The next step of the algorithm consists of providing scores for
each flux distribution. The scores are calculated by subtracting
half the number of active low confidence reactions from the
number of active medium confidence reactions. If a score is
positive, it means that adding the reactions associated with this flux
distribution will add to the value of the objective function of the
algorithm. Scores are calculated for each column in the matrix.
This marks the beginning of the third step of the algorithm. This
step involves addition of flux distributions associated with the high
confidence set of reactions. It starts by ordering the list of scores
associated with the flux distributions from high to low values.
Then, the flux distribution with the highest score is checked for
any active high confidence reactions; if there are no high
confidence reactions, then the flux distribution with the second
highest score is checked for high confidence reactions. This
procedure continues until the highest scoring flux distribution
containing at least one high confidence reaction is found. All of the
active reactions within this flux distribution are added to a final list
of reactions. Also, any high confidence reactions added to the final
list of reactions are removed from the list of remaining high
confidence reactions. Then, the rows of the fdMatrix which are
associated with the set of active reactions that were recently added
to the final list of reactions are set to rows filled with zeros. This is
done because these reactions are now in the final list of reactions
and therefore do not contribute to the objective score anymore.
Changing the values in the rows changes the scores associated with
each column/flux distribution in fdMatrix, thus the scores must be
re-calculated to reflect the changes in the rows. These re-
calculated scores are sorted again to reveal the columns/flux
distributions with the highest scores. Then, the highest scoring
column/flux distribution with at least one reaction that is in the list
of remaining high confidence reactions is selected, and the whole
cycle repeats itself. This cycle is repeated until there are no
reactions left in the list of remaining high confidence reactions,
which means that all of the high confidence reactions were added
to the list of final reactions, which is one of the requirements of the
algorithm. Also, it’s important to note that the high confidence
reactions were added in a way that maximizes the score/objective
function of the algorithm.
The next step of the algorithm involves adding other flux
distributions that increase the value of the objective function. After
adding all of the high confidence reactions, the number of medium
confidence reactions added to the reconstruction was optimized.
The process for adding flux distributions that adds a positive value
to the objective function is very similar to the process that added
all of the high confidence reactions. Each of the remaining flux
distributions is assigned an objective score based on the number of
medium confidence reactions and low confidence reactions
remaining within that distribution. These scores are sorted to find
the distribution with the highest objective value. If the highest
objective score is above zero, then the reactions of that distribution
are added to the reconstruction. Then, the rows that correspond to
the reactions that were just added are filled with zeros to prevent
double counting toward the objective function. This process is
repeated as long as the highest objective score is greater than zero.
This means that reactions are added only if the corresponding
distributions increase the objective function, and reactions are no
longer added when the objective function cannot be increased by
the randomly created distributions, meaning that the objective
function is at a maximum for this particular set of flux
distributions.
Then, this whole process is repeated again; a new set of random
flux distributions is created based on the partial model this time
(the distributions were created from the general model the first
time), and reactions from the high confidence list are added along
with their associated reactions determined by the flux distribu-
tions, and medium confidence reactions are optimized. As part of
the model building algorithm during the reconstruction process,
maximizing the flux to ascertain activity/inactivity of a reaction is
needed. A random flux distribution is used only in the
reconstruction process which is subjected to our algorithm to find
out whether each reaction adds to biological meaning or not. This
process repeats itself until the model doesn’t change in size from
one iteration to the next. The time required to solve a problem
associated with a three tissue system varies from 0.05–0.1 seconds.
The number of reactions maximized in each iteration is variable;
in the first iteration, all reactions are maximized. In the second
iteration, all reactions that had zero flux in the solution to the first
linear programming iteration are maximized, and so on. This
continues until either all reactions are proven to carry a flux (have
a non-zero solution to any linear programming problem), or some
set of reactions are proven to be unable to carry flux (the set of
reactions is maximized/minimized and no flux profiles result). The
latter is explicitly proven by performing distinct linear program-
ming problems and maximizing/minimizing each reaction in the
set individually as explained in f tissue-specific model building
algorithm.
B.5 Validation Procedure
Robustness analysis of the algorithm was performed by
generating 5 replicate models with starting point as 5 different
randomized stoichiometric matrices. All 5 of the replicate models
were similar in size (Figure S15 in File S1), thereby validating the
robustness of the algorithm. Further validations of the model are
described in the following subsections.
B.5.1 OMIM gene deletion analysis. The first validation
procedure uses similar approach as used in studies by Shlomi et al.
The validation tests the effect of deleting genes in silico versus
experimental data. The experimental phenotypic effect of deleting
genes is available in the public database – OMIM [111]. The
known biomarkers of the amino acid-associated disorders com-
piled above were manually extracted from the disease description
field in the OMIM database. This set of disorders was further
filtered to include only the disorders that were reported to show a
concentration change in at least one of the model’s boundary
metabolites. This resulted in a final set of 17 disorders that
composed the validation set. In this validation, disorders that are
known to increase or decrease amino acid levels in the blood were
Multi-Tissue Computational Modeling in MKR Mice
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considered. This is because the calculated steady state models can
only allow accumulation in the extracellular (blood) compartment.
After mapping OMIM disorder identifier to specific human
genes, reactions associated with the affected genes were found.
Then, those reactions were artificially ‘‘turned on’’ by equating the
lower bounds of the associated reactions to 1. This means that a
flux with zero value through the affected reactions is not
permitted. The purpose of forcing the reactions to be active is to
model a situation in which these reactions are used; this will
provide a greater contrast for when the reactions are removed (if
zero flux is still allowed, then the model may not use the affected
reactions and therefore the comparison would be between
reactions that may not be used and reactions that are deactivated).
After the lower bounds are changed, flux variability analysis is
performed on the model [112] providing a minimum and
maximum flux allowed by the solution space of the model. Then,
the two sets of flux bounds are compared to determine if the
reactions are upregulated, downregulated or unchanged. The
reactions are considered either upregulated or downregulated if
the change in flux bounds is greater than a threshold, or less than
the negative of that same threshold. The change between the sets
of flux bounds is calculated by:
For reaction ‘i’:
Disease reaction flux , wild-type reaction flux if,
diseaseMin(i)zM(i)vrefMin(i)½ AND diseaseMax(i)ƒrefMax(i)½ 
OR
diseaseMin(i)ƒrefMin(i)½ AND diseaseMax(i)zM(i)vrefMax(i)½ 
Disease reaction flux . wild-type reaction flux if,
diseaseMin(i)w refMin(i)zM(i)ð Þ½ AND diseaseMax(i)§refMax(i)½ 
OR
diseaseMin(i)§refMin(i)½ AND diseaseMax(i)w refMax(i)zM(i)ð Þ½ 
Where:
M(i)~"  Dmean refMin(i),refMax(i),diseaseMin(i),diseaseMax(i)ð ÞD
The set of reactions represented by the variable ‘i’ are the set of
exchange reactions of metabolites that have been identified in the
phenotype descriptions of the OMIM database. In this validation,
they are amino acids. The variables diseaseMax and diseaseMin
are the flux bounds of the amino acids in the disease version of the
model with particular genes knocked out. The variables refMin
and refMax are the flux bounds of the amino acids in the healthy
model that has no genes knocked out. The variable e represents
the threshold value used for the receiver-operator characteristic
(ROC) curves.
The results of this validation are depicted via ROC curves in the
Results section. In this simulation, the threshold value is varied to
distinguish between very large changes in flux bounds and very
small changes in flux bounds. Thus, for a given threshold value
and disease, upregulated and downregulated predictions are made
for each amino acid exchange reaction. These predictions are
checked against the known phenotype of that specific disease. This
generates a list of true positive, false positive, true negative, and
false negative predictions for the specific disease at a particular
threshold. This analysis is repeated using the same threshold value
for each disease in the validation. All of the predictions from each
disease are added together, to provide a number of true positives
(TP), false positives (FP), true negatives (TN), and false negatives
(FN) for that particular threshold value. Then, the false positive
rate (FPR) and the true positive rate (TPR) are calculated as below.
FPR~
1{"
1{a"
TPR~
1{"
1z"
Where, a~
1{Po
1zPo
; Po is proportion of unchanged metabolites
in the data; " is the threshold, defined above.
TPR = true positive rate; (number of true positives)/(number
of true positives + number of false negatives).
FPR = false positive rate; (number of false positives)/(number
of false positives + number of true negatives).
These values for FPR and TPR are calculated for a range of
threshold values; typically from 0 to 1000, and plotted with FPR
on the x-axis and TPR is on the y-axis. The area under the curve
(AUC) of this plot is the indicator of the quality of the
reconstruction network. An AUC of 0.5 represents a random
classifier; any AUC over 0.5 represents a system that is better than
a random guessing.
B.5.2 T2DM gene expression fold change analysis. The
gene expression of adipose, liver, and muscle tissue for MKR mice
model was examined. The MKR mouse model was developed by
over-expressing the IGF-I receptor in skeletal muscle [113].
Statistical tests were used to identify genes that were significantly
upregulated or downregulated (p-value ,0.05). These genes were
mapped to Entrez gene IDs, and subsequently mapped to the
steady-state model. This identified specific reactions that were
either upregulated or downregulated due to differential gene
transcription in type II diabetes. For reactions that had both
upregulated and downregulated genes mapped to them, regulation
status of the reaction was determined by summing the number of
up and downregulated genes that map to that specific reaction in
question and compare the results. This is only done when multiple
gene IDs from the microarray data map to the same Entrez gene
ID; this is not performed in the case where multiple distinct gene
IDs map to the same reaction through gene-to-reaction maps. In
the latter case, the gene-to-reaction logical mapping is used to
determine the regulation status.
Transcription levels of genes do not directly correspond to
reaction fluxes, but a few assumptions can be made to demonstrate
the effect of the levels. The main assumption is that relative gene
transcription levels correlate with relative protein concentrations.
With this assumption, the effect of increased or decreased protein
concentration manifests itself in the upper and lower bounds of the
reactions that are associated with the protein. The reason for this is
because enzyme concentration only affects Vmax in enzyme
kinetics equations. Vmax is equal to kcat multiplied by enzyme
concentration; therefore, a lower enzyme concentration decreases
the maximum reaction velocity (and minimum reaction velocity, if
the reaction is reversible). Reactions that are determined to be
affected by gene regulation have upper bounds initially set to 100
and lower bounds initially set to 2100 or 0 depending on
Multi-Tissue Computational Modeling in MKR Mice
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reversibility. Unaffected reactions have normal reaction bounds
(upper bounds are 1000 and lower bounds are 21000 or 0). Initial
FVA is then performed. Then, upregulated reactions have bounds
doubled downregulated reactions have bounds halved. Then, FVA
is performed, and resulting bounds are compared to initial FVA
results for comparison and analysis. The reasoning for initially
changing affected reaction bounds from 1000 to 100 was to
magnify the effect of upgregulating reactions. If reaction bounds of
affected reactions are kept at normal 1000 values, then doubling
the reaction bounds due to upregulation may not display
downstream upregulation or display the far-reaching effects of
gene upregulation. The lower bound and upper bound for
exchange reactions are 1 and 1000 respectively.
The first step is to identify all upregulated and downregulated
reactions, and change the associated bounds to one-tenth of the
initial value. This is done so that the effect of increases in reaction
bounds due to upregulation will have an effect in a steady-state
model. Then, FVA is performed on the model to establish a
control set of bounds. After that, the bounds of upregulated
reactions are doubled and downregulated reactions are halved.
Then, FVA is performed again to generate a disease-state set of
bounds. Then, the difference between the two sets of bounds is
determined by the following:
For a given reaction ‘i’;
change(i)~
diseaseMin(i){refMin(i)ð Þz diseaseMax(i){refMax(i)ð Þ
DM(i)D
diseaseMin,diseaseMax½  represent the lower and upper bounds
of the disease set.
refMin,refMax½  represent the lower and upper bounds of the
control set.
DM(i)D is the absolute value of the mean of all four bounds for
reaction ‘i’.
Literature results were obtained for specific concentrations of
amino acids in the plasma for T2DM rat versus healthy rat. The
effect on each of the transport fluxes of each amino acid were
considered to determine an increase or decrease in concentration
in the plasma. This was done instead of simply inspecting the
exchange reactions for each amino acid because the full effect of
the gene expression changes may not be observed on an exchange
reaction if an unaffected pathway exists that involves the exchange
reaction in question. Taking all transport reactions into account
generates a more complete picture of the uptake or secretion of
metabolites.
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